Document is current

Any future updates will be listed below

A real-world pharmacovigilance study of belzutifan in renal cell carcinoma and von Hippel-Lindau disease: insights from the FDA adverse event reporting system database

Crossref DOI link: https://doi.org/10.1007/s11096-025-01953-9

Published Online: 2025-06-16

Published Print: 2025-10

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark